التداخل بين كوريوغونادوتروبين ألفا وموجهة الغدد التناسلية المشيمائية

Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis.

Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS during or following treatment with PREGNYL.

Adherence to the recommended PREGNYL dose and treatment regimen and careful monitoring of ovarian response is important to reduce the risk of OHSS.

Advise women of the potential risk of multiple births before starting treatment with gonadotropins including PREGNYL.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PREGNYL and any potential adverse effects on the breastfed child from PREGNYL or from the underlying maternal condition.